Search
Emicizumab
go.drugbank.com/drugs/DB13923ApprovedInvestigational[A31279, L1016] It was created by Chugai Pharmaceuticals Co. Ltd. and co-developed with Roche and Genentech.[L1015] … The ability of Emicizumab to bind to all these three different factors allows it to overcome immunogenicity and unstable hemostatic efficacy produced by previous Factor VII agents.
Vasopressin
go.drugbank.com/drugs/DB00067ApprovedInvestigational[A228013] Despite a wide variety of functions, exogenous vasopressin is primarily used to control blood pressure during systemic shock by increasing vasoconstriction and renal fluid reuptake by acting … [A228013] It is currently marketed under the trademark VASOSTRICT® by PAR Pharmaceuticals.[L31413]
Ferumoxytol
go.drugbank.com/drugs/DB06215ApprovedInvestigationalhigh dose by rapid intravenous injection [L2181]. … [L54506] It is comprised of superparamagnetic iron oxide nanoparticles which are coated by a semi-synthetic carbohydrate shell in an isotonic, neutral pH solution that may be administered at relatively
Odesivimab
go.drugbank.com/drugs/DB15900ApprovedInvestigationalINMAZEB™ is produced by Regeneron Pharmaceuticals and was granted FDA approval on October 14, 2020.[L17320]
Eravacycline
go.drugbank.com/drugs/DB12329ApprovedInvestigationalIt was first approved by the FDA on August 27, 2018 [L4540]. … Eravacycline, known as _Xerava_ by Tetraphase Pharmaceuticals, is a fully synthetic fluorocycline antibiotic of the tetracycline class with activity against clinically significant gram-negative, gram-positive
Chikungunya virus Senegal strain 37997 capsid protein
go.drugbank.com/drugs/DB21766ApprovedInvestigationalOne of three components of a recombinant Chikungunya virus vaccine called Vimkunya.
Chikungunya virus Senegal strain 37997 envelope protein E2
go.drugbank.com/drugs/DB21768ApprovedInvestigationalOne of three components of a recombinant Chikungunya virus vaccine called Vimkunya.
Defactinib
go.drugbank.com/drugs/DB12282ApprovedInvestigational[L53208,A273943] Defactinib was approved by the US FDA in May 2025 in a co-package alongside [avutometinib] (called Avmapki Fakzynja) for the treatment of recurrent KRAS-mutated low-grade serous ovarian
Methylphenobarbital
go.drugbank.com/drugs/DB00849ApprovedIt has been used for similar purposes, especially in epilepsy, but there is no evidence mephobarbital offers any advantage over phenobarbital.
Isatuximab
go.drugbank.com/drugs/DB14811ApprovedInvestigational[L12099,L12102] It is manufactured by Sanofi-Aventis U.S. under the brand name Sarclisa.[L12102] … [L12099] It is a cytolytic antibody targeted against CD38, a glycoprotein found on the surface of some immune cells that is highly expressed by malignant plasma cells in multiple myeloma.